Navigation Links
Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
Date:6/5/2008

- Phase II Data Indicate Overall and Disease-Free Survival -

WAYNE, N.J., June 5 /PRNewswire/ -- Results from an adjuvant trial in high-risk melanoma patients demonstrated that a majority of patients treated with Leukine(R) (sargramostim) achieved disease-free and/or overall survival. These findings, which indicate Leukine's potential in this cancer setting, were released at the 44th annual meeting of the American Society of Clinical Oncology (ASCO).

Results from the Phase II study (ASCO abstract #20027) show that 60 percent of the 45 high-risk patients enrolled in the trial experienced disease-free survival and 64 percent of patients achieved overall survival at 21 months.

"Previous findings suggest that sargramostim may be a potential adjuvant therapy for high-risk melanoma patients," said E. George Elias M.D., Ph.D., Director of Maryland Melanoma Center. "The percentage of patients who achieved disease-free and overall survival in this trial provides further evidence that sargramostim may prove to be a viable treatment option for this patient population and that further study in Phase III trials are needed."

In this trial, adjuvant therapy with Leukine and a synergistic cytokine, IL-2, was generally well-tolerated in patients with high-risk melanoma following potentially curative surgery. Each patient received two years of adjuvant therapy: year one with Leukine and IL-2 and year two with only Leukine. Toxicities were mild to moderate and no hospitalizations were required.

"These data, particularly the overall survival rates, are encouraging, even though preliminary, and indicate Leukine's potential as a treatment in this setting," said Paul MacCarthy, M.D., FRCPI, vice president and head of U.S. Medical Affairs for Bayer HealthCare Pharmaceuticals.

Clinical Trial Overview

This Phase II trial was a single-arm, open-labeled study to evaluate the safety, tolerability and treatment efficacy of Leukine and I
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
2. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
3. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
4. Wound Management Technologies, Inc. Announces Evidence Based Study
5. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
6. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
7. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Study Findings Show Infection Control Intervention Helps Keep Kids in School
10. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
11. Study Finds Disparities in Breast Cancer Treatment Even Among Fully-Insured African-American and Caucasian Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Apnea Sciences ( www.apneasciences.com ) ... Aliso Viejo , California.  Jimmy ... tremendous growth and worldwide expansion, a new facility with ... the anti snore cure have exceeded our expectations and ... are now in 23 countries and will be increasing ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... of the "Investment Analysis of the US ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... US medical device sector identifies the key trends ... capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... 1 /PRNewswire/ - ImmunoVaccine Technologies, (IVT),patented depot ... with single-dose efficacy achieved in therapeutic,cancer and ... of this,research will be presented October 4th ... from the University of Miami will also ...
... testing give women answers about their ... ... U.S. Cancer,Statistics Working Group (2007), an estimated 182,460 new cases of breast,cancer ... resulting in the earlier detection of the disease when it is,more easily ...
Cached Medicine Technology:ImmunoVaccine Technologies' DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases 2Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center 2Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center 3Good Samaritan Hospital Launches High Risk Breast Cancer Program at Good Samaritan North Health Center 4
(Date:12/26/2014)... Abilene, Texas (PRWEB) December 26, 2014 Yisrayl ... has written an open letter in light of the Ferguson, ... year history of civil unrest and explains why it has ... the reason mankind was even created. He says there is ... in detail. Yisrayl also says there is a set of ...
(Date:12/26/2014)... 2014 “Many people become overwhelmed by ... claim issues and phone calls with insurance companies,” The ... featuring their free eBook on pedestrian and bicycle ... pedestrian and bicycle auto accident claims assures the injured ... of professionally handling their case while they focus on ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a ... producing and marketing of a series of induction heating ... new series of induction brazing equipments . , ... induction brazing refers to the joining of two ... heat. The manager says that there are fundamental differences ...
(Date:12/25/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... This report provides a basic overview of the industry ... part, the report presents the company profile, product specifications, ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... According to a recent Washington Post study, approximately 20% ... psychologically damaged. Among them are a substantial number with ... suicide among PTSD sufferers has become unacceptable to Army ... research from Tel Aviv University, however, doctors will now ...
... , , , ... NEW YORK, Sept. 2 Today, Tim Gunn, television host and ... officer of Liz Claiborne, Inc., is hosting the Ad dressing Psoriasis(TM) ... fashion show recognizes people with moderate to severe plaque psoriasis who have ...
... fibrillation patients drink lots of coffee, don,t eat right, ... People who drink lots of coffee but who don,t ... atrial fibrillation, a new study shows. , Italian researchers ... heart arrhythmia to supply information about their dietary habits, ...
... , , , ... FTER), which, through its ABTTC Inc. division, provides drug and ... with the highest levels of accreditation, announced today that its ... Gaskin on the Company,s recent successes, management team and shareholder ...
... Fla., Sept. 2 Cinergy Health, a nationwide provider of Limited ... chief medical director. As Cinergy Health,s chief medical director, Dr. Lewin ... studies and emerging research to the doctor patient relationship and health ... have Dr. Lewin join the Cinergy Health team," said Daniel Touizer, ...
... , INDIANAPOLIS, Sept. 2 Eli Lilly and Company ... given the Epsilon "Star of Highest Magnitude" Award and has been ... Data Processing Associates (BDPA) and WorkplaceDiversity.com. The Epsilon Award is ... a workplace and environment that supports the advancement of African-Americans in ...
Cached Medicine News:Health News:Keeping the suicidal soldier alive 2Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 2Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 3Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 4Health News:Tim Gunn Hosts Addressing Psoriasis(TM) Fashion Show to Raise Awareness of Psoriasis 5Health News:Caffeine Without Healthy Diet Linked to Heart Risk 2Health News:Forterus Inc. Treatment Centers Showing Consistent, Sustainable Growth; CEO Paul Howarth Interviewed 2Health News:Cinergy Health Names Dr. Margaret Lewin Chief Medical Director 2Health News:Lilly Named Best Company for Blacks in Technology 2
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
The Uro San® Plus male external catheter is a latex catheter with a double-sided adhesive and Shield Skin Protective Dressing....
... Mentor Freedom Pak Seven Starter ... week's supply of Freedom Clear ... all 100% latex-free ... for your convenience and comfort. ...
Medicine Products: